PROMIS NEUROSCIENCES INC. Depreciation
PROMIS NEUROSCIENCES INC. (PMN) reported Depreciation of $321 for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-03-31
- PROMIS NEUROSCIENCES INC. depreciation for the quarter ending 2023-12-31 was -$1.00, a 100.27% decline year-over-year.
- PROMIS NEUROSCIENCES INC. depreciation for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. depreciation for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. depreciation for the quarter ending 2023-03-31 was $322.00, a 81.91% decline year-over-year.
- PROMIS NEUROSCIENCES INC. depreciation for fiscal 2023 was $321.00, a 94.78% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. depreciation for fiscal 2022 was $6.14K, a 84.86% decline from fiscal 2021.
- PROMIS NEUROSCIENCES INC. depreciation for fiscal 2021 was $40.58K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.00 derived: sum of 2 quarters · filed 2025-03-31 | -$1.00 derived: sum of 3 quarters · filed 2025-03-31 | $321.00 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $322.00 10-Q · filed 2024-11-14 | $695.00 derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $322.00 10-Q · filed 2024-08-08 | $695.00 derived: sum of 3 quarters · filed 2024-08-08 | $2.58K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $322.00 10-Q · filed 2024-05-14 | $695.00 derived: sum of 2 quarters · filed 2024-05-14 | $2.58K derived: sum of 3 quarters · filed 2024-05-14 | $4.69K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $373.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.26K derived: sum of 2 quarters · filed 2024-04-01 | $4.36K derived: sum of 3 quarters · filed 2024-04-01 | $6.14K 10-K · filed 2024-04-01 |
| 2022-09-30 | $1.88K 10-Q · filed 2022-11-14 | $3.99K derived: sum of 2 quarters · filed 2022-11-14 | $5.77K 10-Q · filed 2023-11-14 | $14.01K derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-06-30 | $2.11K 10-Q · filed 2022-08-12 | $3.89K 10-Q · filed 2023-08-14 | $12.13K derived: sum of 3 quarters · filed 2023-05-15 | $22.99K derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $1.78K 10-Q · filed 2023-05-15 | $10.02K derived: sum of 2 quarters · filed 2023-05-15 | $20.88K derived: sum of 3 quarters · filed 2023-05-15 | $31.63K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $8.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $19.10K derived: sum of 2 quarters · filed 2023-03-08 | $29.85K derived: sum of 3 quarters · filed 2023-03-08 | $40.58K 10-K · filed 2023-03-08 |
| 2021-09-30 | $10.86K 10-Q · filed 2022-11-14 | $21.61K derived: sum of 2 quarters · filed 2022-11-14 | $32.34K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $10.75K 10-Q · filed 2022-08-12 | $21.48K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |